secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2026-08-10T20:11:49+00:00
Accession:  0001193125-26-342397
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney Q2 2026 loss $46.4M, cash $181.6M; PROACT 1 interim enrollment complete
--------------------------------------------------------------------------------

- Completed enrollment for PROACT 1 accelerated approval analysis (~320 pts); topline eGFR slope results expected Q2 2027.
- Full enrollment of ~470 patients on track for H2 2026; confirmatory results anticipated H2 2029.
- Appointed Kenneth Locke as CTO in June 2026; 25+ years R&D/CMC/supply chain experience.
- Cash and equivalents $181.6M at June 30, 2026, down from $224.9M at March 31, 2026; supports ops into mid-2027.
- Net loss before noncontrolling interest $46.4M in Q2 2026 vs $37.0M in Q2 2025; R&D expenses rose to $36.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000119312526342397/0001193125-26-342397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000119312526342397/prok-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer